VCE-003.2 is a second-generation of semi-synthetic cannabinoid derived of natural non-psychotropic cannabigerol. VCE-003.2 has a neuroprotective effect on different neurons cells. It is able to diminish clinical symptoms in mice models of Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Parkinson’s Disease. The VCE-003.2 mechanism of action on these mice models is made through PPARγ modulation.
Currently, the development program is focused on Huntington’s Disease (HD). The role of PPARγ as a therapeutic target in HD has been recently proved (Chiang et al., 2015). It is a rare neurodegenerative and genetic disease with no available treatments that cure or stop the progression of the disease. VCE-003.2 prevented medium spiny DARPP32+ neuronal loss in these HD mice models improving motor deficits, reactive astrogliosis and microglial activation. In the 3NP model VCE-003.2 inhibited the upregulation of proinflammatory markers and improved antioxidant defenses in the brain. VCE-003.2 improved the motor deficits of 3NP-lesioned mice by reducing hindlimb clasping, dystonia, kyphosis, and locomotor activity.